[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Geron Corp (GERN)

Geron Corp (GERN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,000,773
  • Shares Outstanding, K 641,521
  • Annual Sales, $ 183,880 K
  • Annual Income, $ -83,500 K
  • EBIT $ -35 M
  • EBITDA $ -39 M
  • 60-Month Beta 0.60
  • Price/Sales 5.44
  • Price/Cash Flow N/A
  • Price/Book 4.36

Options Overview Details

View History
  • Implied Volatility 100.13% (+0.33%)
  • Historical Volatility 49.68%
  • IV Percentile 24%
  • IV Rank 7.62%
  • IV High 429.98% on 10/10/25
  • IV Low 72.92% on 03/20/26
  • Expected Move (DTE 6) 0.1105 (7.37%)
  • Put/Call Vol Ratio 0.26
  • Today's Volume 54
  • Volume Avg (30-Day) 790
  • Put/Call OI Ratio 0.34
  • Today's Open Interest 59,132
  • Open Int (30-Day) 55,456
  • Expected Range 1.3895 to 1.6105

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.01
  • Number of Estimates 3
  • High Estimate $0.00
  • Low Estimate $-0.01
  • Prior Year $-0.02
  • Growth Rate Est. (year over year) +50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0800 +38.89%
on 06/11/26
1.6200 -7.41%
on 07/09/26
+0.4000 (+36.36%)
since 06/10/26
3-Month
1.0800 +38.89%
on 06/11/26
1.8000 -16.67%
on 04/14/26
-0.1700 (-10.18%)
since 04/10/26
52-Week
1.0400 +44.23%
on 11/07/25
2.0100 -25.37%
on 02/19/26
+0.1200 (+8.70%)
since 07/10/25

Most Recent Stories

More News
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., June 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective June 17, 2026, it granted stock options...

GERN : 1.5000 (-3.85%)
Geron to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

FOSTER CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today...

GERN : 1.5000 (-3.85%)
Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:GERN),(NASDAQ:BIOA),(NYSE:LCTX),(NASDAQ:FATE) EQNX::TICKER_END

AVAI : 0.1750 (+3.24%)
BIOA : 24.34 (-2.21%)
LCTX : 1.2800 (-0.78%)
GERN : 1.5000 (-3.85%)
FATE : 3.10 (-0.32%)
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective May 15, 2026, it granted stock options...

GERN : 1.5000 (-3.85%)
First Real-World Evidence Study of RYTELO® (imetelstat) in Lower-risk Myelodysplastic Syndromes (LR-MDS) to be Presented at EHA 2026 

Investigator-sponsored study, conducted at the Moffitt Cancer Center, demonstrates safety and efficacy consistent with the Phase 3 IMerge trial in a broader patient population  Additional presentations...

GERN : 1.5000 (-3.85%)
Geron: Q1 Earnings Snapshot

Geron: Q1 Earnings Snapshot

GERN : 1.5000 (-3.85%)
Geron Corporation Reports First Quarter 2026 Financial Results and Recent Business Highlights

Achieved $51.8 million in RYTELO ® (imetelstat) net product revenue in Q1 2026, an increase of 8% compared to the fourth quarter 2025 Reiterated 2026 RYTELO net product revenue and total operating...

GERN : 1.5000 (-3.85%)
Geron's First Commercial Quarter Tests Whether Rytelo Launch Momentum Holds

Barchart Research What to Expect from GERN Earnings GERN Generated May 5, 2026 Current Price $1.6500 EPS Estimate $$-0.03 Consensus Rating Moderate Buy Average Move 8.78% Geron's First Commercial Quarter...

GERN : 1.5000 (-3.85%)
Geron Plans to Present at Upcoming Investor Conferences

FOSTER CITY, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today...

GERN : 1.5000 (-3.85%)
Geron Plans to Announce First Quarter 2026 Financial Results on May 6, 2026

FOSTER CITY, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today...

GERN : 1.5000 (-3.85%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 70%. The market has dropped from overbought territory. Beware of a potential mean reversion.

See More Share

Business Summary

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic...

See More

Key Turning Points

3rd Resistance Point 1.6567
2nd Resistance Point 1.6133
1st Resistance Point 1.5567
Last Price 1.5000
1st Support Level 1.4567
2nd Support Level 1.4133
3rd Support Level 1.3567

See More

52-Week High 2.0100
Fibonacci 61.8% 1.6395
Fibonacci 50% 1.5250
Last Price 1.5000
Fibonacci 38.2% 1.4105
52-Week Low 1.0400

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.